secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001831283-22-000037
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio Q1 net loss narrows to $27.7M; cash $389.1M; mavacamten FDA approval
----------------------------------------------------------------------------

- Net loss of $27.7M vs $61.6M in Q1 2021; R&D expenses fell to $12.3M from $53.4M.
- Cash balance $389.1M as of March 31, 2022; runway projected through mid-2024.
- Partner BMS received U.S. FDA approval for mavacamten in obstructive HCM in April 2022.
- Partner Tarsus reported positive Phase 3 Saturn-2 data for TP-03 in Demodex blepharitis; NDA planned H2 2022.
- Pfizer agreed to acquire development partner ReViral (sisunatovir); LianBio expects to start three Phase 3 trials in China by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000037/0001831283-22-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000037/lian-20220512.htm
  HTML page:      https://secwatch.observer/filing/0001831283-22-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer